Literature DB >> 8182945

Expression of the FLT3 gene in human leukemia-lymphoma cell lines.

N DaSilva1, Z B Hu, W Ma, O Rosnet, D Birnbaum, H G Drexler.   

Abstract

The FLT3 gene encodes a protein that appears to function as a receptor for a hematopoietic growth factor; together with the KIT and FMS receptors, FLT3 belongs to the superfamily of receptors with tyrosine kinase activity. We examined the expression of FLT3 mRNA in 36 human leukemia-lymphoma cell lines using Northern blot analysis. FLT3 transcripts were found in seven of seven pre B-ALL cell lines (derived from cases with pre B-acute lymphoblastic leukemia or chronic myeloid leukemia in lymphoid blast crisis), and in one of six B-cell lines (namely in a cell line established from a hairy cell leukemia). FLT3 message was not detected in five T-cell, five myeloid, four monocytic, four erythroid and five megakaryocytic cell lines. Two major mRNA species were expressed differentially by positive cell lines. KIT mRNA expression was also investigated in the same panel of cell lines, but was found only in cell lines with erythroid and megakaryocytic features (and not in any of the FLT3-positive cell lines). The pattern of expression of FLT3 contrasts with the transcription of FMS and KIT and suggests that the FLT3 product may play a role primary in immature lymphoid cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8182945

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  7 in total

Review 1.  Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation.

Authors:  Hitoshi Kiyoi; Tomoki Naoe
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

Review 2.  Clinical significance of FLT3 in leukemia.

Authors:  Hitoshi Kiyoi; Masamitsu Yanada; Kazutaka Ozekia
Journal:  Int J Hematol       Date:  2005-08       Impact factor: 2.490

3.  Development and Characterization of FLT3-Specific Curcumin-Loaded Polymeric Micelles as a Drug Delivery System for Treating FLT3-Overexpressing Leukemic Cells.

Authors:  Singkome Tima; Siriporn Okonogi; Chadarat Ampasavate; Chad Pickens; Cory Berkland; Songyot Anuchapreeda
Journal:  J Pharm Sci       Date:  2016-10-14       Impact factor: 3.534

Review 4.  FLT3 INHIBITORS: RECENT ADVANCES AND PROBLEMS FOR CLINICAL APPLICATION.

Authors:  Hitoshi Kiyoi
Journal:  Nagoya J Med Sci       Date:  2015-02       Impact factor: 1.131

Review 5.  Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells.

Authors:  Maryam Abbaspour Babaei; Behnam Kamalidehghan; Mohammad Saleem; Hasniza Zaman Huri; Fatemeh Ahmadipour
Journal:  Drug Des Devel Ther       Date:  2016-08-01       Impact factor: 4.162

Review 6.  An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment.

Authors:  Tiziana Grafone; Michela Palmisano; Chiara Nicci; Sergio Storti
Journal:  Oncol Rev       Date:  2012-04-17

7.  FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia.

Authors:  Benjamin H Lee; Zuzana Tothova; Ross L Levine; Kristina Anderson; Natalija Buza-Vidas; Dana E Cullen; Elizabeth P McDowell; Jennifer Adelsperger; Stefan Fröhling; Brian J P Huntly; Miloslav Beran; Sten Eirik Jacobsen; D Gary Gilliland
Journal:  Cancer Cell       Date:  2007-10       Impact factor: 31.743

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.